Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

disorder that causes exceptionally high levels of LDL-cholesterol. After appropriate clinical development, the next indication pursued for mipomersen will be for other patients with high cholesterol at high risk of cardiovascular events.

Deal Terms

Isis will transition development responsibility for mipomersen to Genzyme over the next two years. In addition to the up-front payment, Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments.

Genzyme and Isis will share mipomersen profits 50/50 when annual worldwide revenues reach $2 billion or more. The profit share begins with a 70/30 Genzyme/Isis split and reaches 50/50 on a sliding scale as annual revenues ramp up to $2 billion.

"Genzyme is reconfirming its 2008 and five-year earnings guidance, and we will manage the financial impact of this agreement within our previously stated goal of 20 percent compound annual growth in non-GAAP earnings per share through 2011," noted Mr. Termeer.

"We believe the profit sharing transaction we have structured with Genzyme is uniquely beneficial to Isis," added Dr. Crooke. "It allows us to benefit in the short term and over time through up-front licensing fees and milestones, while retaining substantial economic participation in the commercialization of the drug. We look forward to working with Genzyme on mipomersen as well as potentially on drugs for CNS and certain rare diseases."

Closure of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

About Familial Hypercholesterolemia (FH)

FH patients have high blood concentrations of LDL-cholesterol due to a genetic disorder which prevents proper metabolism of LDL-cholesterol. These patients experience a markedly increased risk of premature cardiovascular diseases (CVD) and CVD-related death. Familial hypercholestero
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Join Forces to Promote Early Detection ... and Treatment of Hypertension in the UK, NEW ... (Tel Aviv Stock Exchange: INCR), and Omron Healthcare (UK),Ltd., a ... strengthen the link between hypertension diagnostics and,therapies in the professional ...
... Vical Incorporated,(Nasdaq: VICL ) today announced the ... Andrew R. de Guttadauro as Vice President, Corporate,Development. ... was Senior Director of,Strategy at Biogen Idec since ... development of that company,s Zevalin,the first radioimmunotherapy product ...
... Sales Team Forming and Increased Space, Poised for Market ... Technologies,Inc., which is developing innovative devices for the treatment ... VP of Sales, Joseph W.,Rafferty, and has started building ... first product, Pathway PV(TM) Atherectomy System. Recently Pathway ...
Cached Biology Technology:InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 2InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 3InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 4Vical Names Andrew de Guttadauro Vice President, Corporate Development 2Vical Names Andrew de Guttadauro Vice President, Corporate Development 3Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... The National Science Foundation announced this month that it ... of Illinois aimed at understanding how and whether ... support the emerging biofuels industry. The $2 million ... to institutions engaged in engineering infrastructure research. The Illinois ...
... University neuroscientists has discovered patterns of brain activity that may ... structure of objects. Computers can beat us at math ... (That,s why some Web sites use object recognition tasks as ... to us to describe a teapot as having a C-shaped ...
... pleased to inform patients that the European Committee for ... (azacitidine) a positive opinion for the treatment of myelodysplastic ... cell transplants. The CHMP,s positive opinion is ... an overall, unprecedented survival benefit for higher-risk MDS patients. ...
Cached Biology News:NSF funds research at Illinois on sustainable biofuels infrastructure 2NSF funds research at Illinois on sustainable biofuels infrastructure 3How we see objects in depth: The brain's code for 3-D structure 2How we see objects in depth: The brain's code for 3-D structure 3
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... converts any scanner into a gel densitometer. ... features, the basic operation simply consists of ... etc.) into pixel density / intensity values ... Turn your scanner into a high ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... effectively in tubes and 96 well plates. microCLEAN ... one and a half spin DNA cleanup reagent. ... concentrate any type of double stranded DNA, efficiently ... dNTPs (labelled or unlabelled). It is therefore ideally ...
Biology Products: